Ajay K. Nooka, MD, MPH
  Program Co-Chair
  Professor, Department of Hematology and Medical Oncology
  Director, Myeloma Program
  Associate Director, Clinical Research
  Winship Cancer Institute
 Emory University School of Medicine
 Atlanta, GA

Ajay K. Nooka, MD, MPH, is a professor in the Department of Hematology and Medical Oncology at the Winship Cancer Institute of Emory University. He earned his medical degree from Andhra Medical College in India before relocating to the United States. He received his master’s in public health from the University of Texas School of Public Health in Houston, Texas, and then completed his internship and residency at the Northeastern Ohio University College of Medicine. He pursued a fellowship in hematology and oncology at Emory University School of Medicine in Atlanta, Georgia, where he also served as chief fellow before he joined faculty.

Board certified in hematology and medical oncology, Nooka is the director of the Myeloma Program in the Department of Hematology and Oncology at Emory and primarily focuses on multiple myeloma treatment and research. He is also the associate director of clinical research at Winship Cancer Institute. He is involved in numerous professional organizations, including the International Myeloma Working Group of the International Myeloma Society, the American Society of Clinical Oncology, the American Society of Hematology, and the American Society for Transplantation and Cellular Therapy. Nooka’s interests as a clinical investigator focus on multiple myeloma and bone marrow transplant. His research interests include integrating molecular and clinical data to risk-stratify myeloma and to evaluate newer myeloma therapeutic strategies aimed at prolonging survival in myeloma patients.

In addition to leading several investigator-initiated and industry-sponsored clinical trials, he is a recipient of several awards and grants and has published more than 300 articles and abstracts in high-quality peer-reviewed journals including New England Journal of Medicine, Journal of Clinical Oncology, Blood, Leukemia, Lancet Oncology, Blood Advances, Blood Cancer Journal, and Cancer. He serves as a section editor for Cancer, is associate editor for Clinical Lymphoma, Myeloma and Leukemia and is on the editorial board of the American Journal of Clinical Oncology. He is an invited or ad hoc reviewer for several prestigious journals including Journal of Clinical Oncology, Lancet Oncology, Leukemia, Cancer, Blood Advances, Blood Cancer Journal, American Journal of Hematology, British Journal of Hematology, Bone Marrow Transplantation, and Biology of Blood and Marrow Transplantation.

Disclosures: Dr. Ajay Nooka, program Co-Chair, is a consultant for Adaptive Biotechnologies, AstraZeneca, Cellectar Biosciences, GlaxoSmithKline, Janssen, K36 Therapeutics, KITE Therapeutics, ONK Therapeutics, OPNA, Pfizer Inc., Sanofi and Sebia. He also receives grant research support from Aduro Biotech, Amgen, Arch Oncology, Bristol Meyers Squibb, Cellectis, Genentech, GlaxoSmithKline, Janseen, OPNA, Karyopharm, Kite Pharma, Merck, Pfizer Inc., and Takeda. 

Disclosure Policy
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed. 

In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated.